IRIS
SANTAMATO, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.779
NA - Nord America 3.351
AS - Asia 1.832
AF - Africa 50
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 19
SA - Sud America 16
Totale 9.072
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.326
IE - Irlanda 1.218
CN - Cina 1.090
UA - Ucraina 822
SE - Svezia 485
FR - Francia 422
IT - Italia 293
IN - India 198
SG - Singapore 181
TR - Turchia 171
FI - Finlandia 132
DE - Germania 124
GB - Regno Unito 121
PK - Pakistan 47
EG - Egitto 35
JP - Giappone 34
PL - Polonia 30
IR - Iran 25
CZ - Repubblica Ceca 23
NL - Olanda 22
CA - Canada 21
AU - Australia 20
BE - Belgio 20
EU - Europa 17
HK - Hong Kong 15
MY - Malesia 14
TH - Thailandia 14
ES - Italia 12
RU - Federazione Russa 11
LY - Libia 9
RO - Romania 9
GR - Grecia 8
TW - Taiwan 8
ID - Indonesia 7
CO - Colombia 5
NZ - Nuova Zelanda 5
SA - Arabia Saudita 5
SI - Slovenia 5
BR - Brasile 4
CH - Svizzera 4
MX - Messico 4
BD - Bangladesh 3
CL - Cile 3
HU - Ungheria 3
NO - Norvegia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
BO - Bolivia 2
CY - Cipro 2
DK - Danimarca 2
ET - Etiopia 2
IL - Israele 2
KR - Corea 2
KZ - Kazakistan 2
MM - Myanmar 2
PS - Palestinian Territory 2
RS - Serbia 2
SC - Seychelles 2
SM - San Marino 2
TN - Tunisia 2
YE - Yemen 2
AR - Argentina 1
EC - Ecuador 1
JO - Giordania 1
MC - Monaco 1
MD - Moldavia 1
MT - Malta 1
NP - Nepal 1
PH - Filippine 1
PT - Portogallo 1
QA - Qatar 1
SY - Repubblica araba siriana 1
VN - Vietnam 1
Totale 9.072
Salva come PNG Salva come JPEG
Città #
Dublin 1.217
Jacksonville 579
Dearborn 430
Chandler 391
Nyköping 339
Nanjing 276
Wilmington 168
Beijing 146
Ashburn 140
Singapore 138
Princeton 135
Nanchang 119
New York 118
San Mateo 94
Ann Arbor 82
Shenyang 56
Boardman 47
Hebei 44
Kunming 42
Tianjin 42
Des Moines 41
Helsinki 41
Seattle 36
Woodbridge 33
Jiaxing 31
Guangzhou 30
Los Angeles 30
Jinan 29
Changsha 27
Ningbo 27
Hangzhou 25
Bari 24
Foggia 24
Pune 24
Zhengzhou 21
Shanghai 19
Munich 18
Hilden 17
Brussels 16
Milan 16
Brno 13
Kraków 13
Lanzhou 13
Flushing 12
Houston 12
Redwood City 12
Rome 12
Changchun 11
Ismailia 11
Kocaeli 11
Lahore 11
San Francisco 11
Bengaluru 10
Berlin 10
London 10
Paris 10
San Genesio Ed Uniti 10
Bangkok 9
Giza 9
Istanbul 9
Taizhou 9
Tripoli 9
Wuhan 9
Faisalabad 8
Athens 7
Lethbridge 7
Norwalk 7
Ankara 6
Auburn Hills 6
Fuzhou 6
Hefei 6
Independence 6
Islamabad 6
Kuala Lumpur 6
Saint Petersburg 6
Taipei 6
Al Mansurah 5
Chicago 5
Delhi 5
Duncan 5
Düsseldorf 5
Las Vegas 5
Mountain View 5
New Orleans 5
Oulu 5
Verona 5
Warsaw 5
Washington 5
Ahmedabad 4
Birmingham 4
Bloomington 4
Chennai 4
Florence 4
Gdansk 4
Hyderabad 4
Jakarta 4
Jeddah 4
Naples 4
Nishigaoka 4
Norwich 4
Totale 5.569
Salva come PNG Salva come JPEG
Nome #
Short-term effects of high-intensity laser therapy versus ultrasound therapy in the treatment of low back pain: a randomized controlled trial. 436
Localized muscle vibration in the treatment of motor impairment and spasticity in post-stroke patients: a systematic review 159
Approccio clinico e riabilitativo alla sindrome da conflitto subacromiale 153
Is Extracorporeal Shockwave Therapy Combined With Isokinetic Exercise More Effective Than Extracorporeal Shockwave Therapy Alone for Subacromial Impingement Syndrome? A Randomized Clinical Trial. 125
The use of alpha-lipoic acid (ALA), gamma linolenic acid (GLA) and rehabilitation in the treatment of back pain: effect on health-related quality of life. 118
VALUTAZIONE BAROPODOMETRICA IN PAZIENTI CON MORBO DI PARKINSON IN FASE INIZIALE,CONFRONTO CON GRUPPO DI CONTROLLO E E SUCCESSIVA VALUTAZIONE DOPO TRATTAMENTO RIABILITATIVO 118
L’attività fisica programmata nella prevenzione dei danni secondari nel bambino diabetico” 115
Lifestyle-related factors in predementia and dementia syndromes. 112
Efficacia comparata tra laser Neodimio YAG e ultrasuoni nel trattamento della sindrome da conflitto sub acromiale 111
Cognitive behavioural group therapy in mild cognitive impairment: intervention with a cognitive or behavioural/psychological focus? 110
Interleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. 110
Botulinum toxin type A in the treatment of focal hand dystonia after surgical treatment for thumb duplication. 110
Treatment of upper limb spasticity after stroke: one-year safety and efficacy of botulinum toxin type A NT201 109
Associated with intrathecal baclofen treatment and duloxetine in patients with multiple sclerosis 103
Late-life depression, mild cognitive impairment, and dementia: possible continuum? 101
Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease. 100
Alcohol drinking, cognitive functions in older age, predementia, and dementia syndromes 100
Beyond coronary artery disease: rosuvastatin in older patients with ischemic systolic heart failure. 99
severe osteoporosis treated with teriparatide in a patient affected by recessive epidermolysis bullosa dystrophica 97
Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study. 97
Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. 91
Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treatment. 90
Progression to dementia in probable and possible mild cognitive impairment 88
Vascular risk factors, alcohol intake, and cognitive decline 87
Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial. 87
SBOTE study: Extracorporeal shock wave therapy versus electrical stimulation after botulinum toxin type a injection for post-stroke spasticity-a prospective randomized trial 86
Lifestyle-related factors in predementia and dementia syndromes. 85
Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy? 84
Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques. 84
Dietary Fatty acids, age-related cognitive decline, and mild cognitive impairment 84
Lipoproteins, vascular-related genetic factors, and human longevity. 83
Current and emerging treatments for amyotrophic lateral sclerosis. 82
L'ESERCIZIO ISOCINETICO 82
Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease. 81
Effect of botulinum toxin type A andmodified constraint-induced movement therapy on motor function of upper limb inchildren with obstetrical brachial plexus palsy 81
Role of biphosphonates and lymphatic drainage type Leduc in the complex regional pain syndrome (shoulder-hand syndrome). 80
Depressive symptoms, vascular risk factors and mild cognitive impairment. The Italian longitudinal study on aging 80
Botulinum toxin type A in the treatment of sialorrhea in Parkinson's disease 80
Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective? 79
Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. 78
Cognitive behavioural group therapy in mild cognitive impairment: intervention with a cognitive or behavioural/psychological focus? 77
Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity 77
Adjuvant treatments associated with botulinum toxin injection for managing spasticity: an overview of the literature 77
Anti-β-Amyloid Immunotherapy forAlzheimer's Disease: Focus on Bapineuzumab. 76
Accuracy of botulinum toxin type A injection into the forearm muscles of chronic stroke patients with spastic flexed wrist and clenched fist: manual needle placement evaluated using ultrasonography. 76
Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms. 75
Botulinum toxin type A in the treatment of painful adductor muscle contracture after total hip arthroplasty. 74
Higher total cholesterol, cognitive decline, and dementia. 73
Lifestyle-related factors, alcohol consumption, and mild cognitive impairment 72
Short-term effects of high-intensity laser therapy versus ultrasound therapy in the treatment of people with subacromial impingement syndrome: a randomized clinical trial 72
Effect of electrical stimulation as an adjunct to botulinum toxin type A in the treatment of adult spasticity: a systematic review 72
Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging 71
Change of diagnoses in probable and possible mild cognitive impairment: the Italian Longitudinal Study on Aging 71
Hypertension and mild cognitive impairment subtypes 70
Effectiveness of the Frequency Rhythmic Electrical Modulation System for the Treatment of Chronic and Painful Venous Leg Ulcers in Older Adults 69
Influence of physician empathy on the outcome of botulinum toxin treatment for upper limb spasticity in patients with chronic stroke: A cohort study 69
Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease 68
Hyperhomocysteinemia in L-dopa treated patients with Parkinson's disease: potential implications in cognitive dysfunction and dementia? 67
Change in Coefficient of Fatigability Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: A Prospective Open-Label Observational Study 67
Development of a patient-centered questionnaire for post-stroke spasticity assessment: a reliability study 67
Short arm of chromosome 11 and sporadic Alzheimer's disease: catalase and cathepsin D gene polymorphisms 67
Possible role of alpha-lipoic acid in the treatment of peripheral nerve injuries. 66
Acoustic analysis of swallowing sounds: a new technique for assessing dysphagia 65
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease 65
Tau aggregation inhibitors: The future of Alzheimers pharmacotherapy? 65
High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective? 65
Mild cognitive impairment: dementia risk factor or high-risk state for progression to dementia? 63
Effectiveness of the Frequency Rhythmic Electrical Modulation System for the Treatment of Chronic and Painful Venous Leg Ulcers in Older Adults. 63
Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. 63
High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis 62
Progresses in treating agitation: a major clinical challenge in Alzheimer's disease 62
Safety and efficacy of incobotulinumtoxin A as a potential treatment for poststroke spasticity 62
Tau-directed approaches for the treatment of Alzheimers disease: Focus on leuco-methylthioninium 62
Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition 62
Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke 61
The role of the rehabilitation in subjects with Progressive Supranuclear Palsy: a narrative review 61
Effect of botulinum toxin type A, motor imagery and motor observation on motor function of hemiparetic upper limb after stroke. 60
Extracorporeal shock wave therapy for the treatment of poststroke plantar-flexor muscles spasticity: a prospective open-label study. 60
Tau-based therapeutics for Alzheimer's disease: Active and passive immunotherapy 60
Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report 59
Parkinson's Disease: New Insights into Pathophysiology and Rehabilitative Approaches 59
Abobotulinumtoxina and rehabilitation vs rehabilitation alone in post-stroke spasticity: A cost-utility analysis 58
Effect of intrathecal baclofen, botulinum toxin type A and arehabilitation programme on locomotor function after spinal cord injury: a casereport. 57
Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. 57
Post-stroke spasticity as a condition: a new perspective on patient evaluation 57
Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review 57
Topical distribution of initial paresis of the limbs to predict clinically relevant spasticity after ischemic stroke: a retrospective cohort study. 56
Does Spasticity Reduction by Botulinum Toxin Type A Improve Upper Limb Functionality in Adult Post-Stroke Patients? A Systematic Review of Relevant Studies. 56
Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature 56
Effects of treadmill training on cognitive and motor features of patients with mild to moderate Parkinson's disease: a pilot, single-blind, randomized controlled trial 56
Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques 56
Current epidemiological approaches to the metabolic-cognitive syndrome. 55
Pulmonary rehabilitation for patients with bronchiectasis: case reports. 55
Management of stroke patients submitted to botulinum toxin type A therapy: a Delphi survey of an Italian expert panel of specialist injectors. 55
Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment 54
Ultrasonographic evaluation of botulinum toxin injection site for the medial approach to tibialis posterior muscle in chronic stroke patients with spastic equinovarus foot: An observational study 53
Postural and balance disorders in patients with Parkinson's disease: A prospective open-label feasibility study with two months of action observation treatment 53
High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy. 52
Effects of Robot-Assisted Training for the Unaffected Arm in Patients with Hemiparetic Cerebral Palsy: A Proof-of-Concept Pilot Study 52
Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke 52
Totale 8.054
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.060
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.060
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.202 0 0 0 0 249 278 267 31 149 37 173 18
2020/20211.182 160 6 129 6 175 63 166 151 167 145 2 12
2021/2022682 100 5 32 32 39 6 17 55 99 57 46 194
2022/20233.070 245 100 88 121 104 205 89 284 1.427 99 164 144
2023/2024584 53 25 25 25 61 238 20 41 7 8 9 72
2024/2025334 131 21 40 92 50 0 0 0 0 0 0 0
Totale 9.477